Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,885,909 papers from all fields of science
Search
Sign In
Create Free Account
Adverse event
Known as:
AdverseEvent
, adverse events
, AE
Expand
Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
Adverse effects
Clinical Data Interchange Standards Consortium Terminology
Complication
Complications and sequelae
Expand
Narrower (5)
Complication surgery/medical treatment
cardiovascular complications
complication of disease
medical complication
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
A. Zelenetz
,
J. Barrientos
,
+21 authors
P. Hillmen
2017
Corpus ID: 3577051
(BR) has been a standard of care for the management of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL…
Expand
Highly Cited
2008
Highly Cited
2008
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
R. Dmochowski
,
P. Sand
,
N. Zinner
,
D. Staskin
Urology
2008
Corpus ID: 11816493
Highly Cited
2008
Highly Cited
2008
A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment
J. Osselaer
,
N. Messe
,
+8 authors
L. Corash
Transfusion
2008
Corpus ID: 28017482
BACKGROUND: Inactivation of pathogens and white blood cells in platelet (PLT) components with amotosalen and UVA light (INTERCEPT…
Expand
Highly Cited
2006
Highly Cited
2006
Massachusetts General Hospital and
2006
Corpus ID: 9398274
Review
2003
Review
2003
Thalidomide: a review of approved and investigational uses.
S. Matthews
,
Christopher M. McCoy
Clinical Therapeutics
2003
Corpus ID: 24496987
Highly Cited
2002
Highly Cited
2002
Evaluating the crash and citation rates of Utah drivers licensed with medical conditions, 1992-1996.
Donald D. Vernon
,
E. Diller
,
Lawrence J. Cook
,
James C. Reading
,
Anthony J Suruda
,
J. Dean
Accident Analysis and Prevention
2002
Corpus ID: 12036320
Highly Cited
2000
Highly Cited
2000
Efficacy of trospium chloride in patients with detrusor instability: a placebo‐controlled, randomized, double‐blind, multicentre clinical trial
L. Cardozo
,
C. Chapple
,
+6 authors
M. Schafer
BJU International
2000
Corpus ID: 39207070
Objectives To assess the efficacy and safety of trospium chloride (TCl, 20 mg twice daily) in the treatment of detrusor…
Expand
Highly Cited
1998
Highly Cited
1998
Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment
R. Toto
,
P. Shultz
,
+5 authors
S. Shahinfar
1998
Corpus ID: 20025617
We evaluated the blood pressure-lowering activity, tolerability, and safety of losartan in 112 hypertensive (sitting diastolic…
Expand
Highly Cited
1997
Highly Cited
1997
Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either…
R. Tyni‐Lenné
,
R. Tyni‐Lenné
,
+7 authors
Christer Sylvén
American Journal of Cardiology
1997
Corpus ID: 45885422
Highly Cited
1995
Highly Cited
1995
Treatment of Hypercholesterolemia in NIDDM With Policosanol
Omayda Torres
,
A. Agramonte
,
J. Illnait
,
R. M. Ferreiro
,
L. Fernández
,
Julio C. Fernández
Diabetes Care
1995
Corpus ID: 30619691
OBJECTIVE To determine whether elevated levels of cholesterol and low-density lipoprotein (LDL) cholesterol in non-insulin…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE